Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

COMPASS Pathways plc (CMPS)

15.77   -0.53 (-3.25%) 01-21 17:49
Open: 16.1 Pre. Close: 16.3
High: 16.8 Low: 15.51
Volume: 411,300 Market Cap: 658M
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.825 - 16.943 16.943 - 17.033
Low: 15.219 - 15.37 15.37 - 15.486
Close: 15.56 - 15.765 15.765 - 15.923

Technical analysis

as of: 2022-01-21 4:25:37 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 24.57     One year: 28.56
Support: Support1: 15.51    Support2: 12.90
Resistance: Resistance1: 21.03    Resistance2: 24.45
Pivot: 18.96
Moving Average: MA(5): 16.80     MA(20): 19.84
MA(100): 30.13     MA(250): 34.59
MACD: MACD(12,26): -2.63     Signal(9): -2.56
Stochastic oscillator: %K(14,3): 2.14     %D(3): 4.64
RSI: RSI(14): 24.71
52-week: High: 58.62  Low: 15.51  Change(%): -63.8
Average Vol(K): 3-Month: 815  10-Days: 453

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CMPS has closed above bottom band by 11.6%. Bollinger Bands are 9.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 19 Jan 2022
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression - Yahoo Finance

Mon, 17 Jan 2022
Brokerages Anticipate COMPASS Pathways plc (NASDAQ:CMPS) to Announce -$0.48 EPS - MarketBeat

Fri, 14 Jan 2022
Psychedelics Approval in Canada | COMPASS Pathways $CMPS - Midas Letter

Mon, 10 Jan 2022
COMPASS Pathways to participate in HC Wainwright investor - GlobeNewswire

Tue, 04 Jan 2022
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology - GlobeNewswire

Thu, 23 Dec 2021
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health - Yahoo Finance

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Care Facilities
Shares Out. (M) 42
Shares Float (M) 18
% Held by Insiders 14.85
% Held by Institutions 19.96
Shares Short (K) 1,520
Shares Short P. Month (K) 809

Stock Financials

EPS -1.680
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 7.320
Profit Margin
Operating Margin
Return on Assets (ttm) -14.0
Return on Equity (ttm) -25.5
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.401
Qtrly Earnings Growth
Operating Cash Flow (M) -62
Levered Free Cash Flow (M) -33

Stock Valuations

PE Ratio -9.39
PEG Ratio
Price to Book value 2.15
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.